

Rosalba Mc Torrasi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1602393/publications.pdf>

Version: 2024-02-01

81
papers

4,055
citations

147786

31
h-index

118840

62
g-index

81
all docs

81
docs citations

81
times ranked

4736
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103280.	4.4	22
2	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 103-109.	2.5	3
3	Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 66-75.	4.4	24
4	Hypofractionated volumetric modulated arc therapy in ductal carcinoma <i>in situ</i> : toxicity and cosmetic outcome from a prospective series. <i>British Journal of Radiology</i> , 2018, 91, 20170634.	2.2	4
5	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 163-169.	0.6	14
6	Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 283-291.	4.4	37
7	Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 437-444.	1.5	19
8	Aromatase inhibitors in premenopause: Great expectations fulfilled?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 82-89.	4.4	5
9	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. <i>Breast</i> , 2016, 26, 11-17.	2.2	51
10	Attitudes on fertility issues in breast cancer patients: an Italian survey. <i>Gynecological Endocrinology</i> , 2015, 31, 458-464.	1.7	36
11	Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series. <i>Oncologist</i> , 2015, 20, 586-592.	3.7	58
12	Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: A single institution experience. <i>Breast</i> , 2013, 22, 419-424.	2.2	11
13	ecancermedalscience. <i>Ecancermedalscience</i> , 2012, 6, 275.	1.1	7
14	Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. <i>Radiation Oncology</i> , 2012, 7, 145.	2.7	72
15	Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluorouracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. <i>Breast</i> , 2011, 20, 34-38.	2.2	8
16	Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. <i>Breast</i> , 2011, 20, 319-323.	2.2	38
17	Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 431-441.	2.5	28
18	Fulvestrant for advanced male breast cancer patients: a case series. <i>Annals of Oncology</i> , 2011, 22, 985.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Reply to S. Goel et al and P.A. Kavsak et al. Journal of Clinical Oncology, 2011, 29, e178-e179.	1.6	0
20	Phase II Trial of Combination of Pegylated Liposomal Doxorubicin, Cisplatin, and Infusional 5-Fluorouracil (CCF) Plus Trastuzumab as Preoperative Treatment for Locally Advanced and Inflammatory Breast Cancer. Clinical Breast Cancer, 2010, 10, 483-488.	2.4	20
21	Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation. Journal of Clinical Oncology, 2010, 28, 3910-3916.	1.6	554
22	Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report. Annals of Oncology, 2010, 21, 667-668.	1.2	7
23	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Annals of Oncology, 2010, 21, 1974-1981.	1.2	202
24	A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer. European Journal of Cancer, 2010, 46, 2216-2224.	2.8	50
25	A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Annals of Oncology, 2009, 20, 1178-1184.	1.2	36
26	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment, 2009, 116, 317-328.	2.5	172
27	Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Research and Treatment, 2009, 116, 359-369.	2.5	86
28	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breast Cancer Research and Treatment, 2009, 118, 385-394.	2.5	31
29	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anti-Cancer Drugs, 2009, 20, 197-203.	1.4	18
30	Preoperative Chemo- and Endocrine Therapy. Cancer Treatment and Research, 2009, 151, 103-120.	0.5	1
31	Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and) Tj ETQq1 1 0.784314 rgBT /Over weekly paclitaxel. Cancer Chemotherapy and Pharmacology, 2008, 62, 667-672.	2.3	81
32	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. British Journal of Cancer, 2008, 99, 1564-1571.	6.4	43
33	Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy. Breast Journal, 2008, 14, 435-441.	1.0	7
34	Topoisomerase III α gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast, 2008, 17, 506-511.	2.2	32
35	Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors. Breast, 2008, 17, 654-660.	2.2	8
36	Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Annals of Oncology, 2008, 19, 465-472.	1.2	89

#	ARTICLE	IF	CITATIONS
37	Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4899-4905.	1.6	280
38	Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. <i>British Journal of Cancer</i> , 2008, 98, 1745-1752.	6.4	21
39	Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. <i>Annals of Oncology</i> , 2008, 19, 1231-1241.	1.2	50
40	Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. <i>Annals of Oncology</i> , 2007, 18, 1632-1640.	1.2	92
41	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , 2007, 18, 1177-1184.	1.2	8
42	HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17. <i>European Journal of Cancer</i> , 2007, 43, 2339-2344.	2.8	54
43	Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. <i>British Journal of Cancer</i> , 2007, 97, 802-808.	6.4	67
44	Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2â€“T4 breast cancer. <i>Breast</i> , 2007, 16, 73-80.	2.2	14
45	Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 97-103.	2.5	8
46	Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. <i>Supportive Care in Cancer</i> , 2007, 15, 1213-1217.	2.2	12
47	Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. <i>BMC Cancer</i> , 2006, 6, 225.	2.6	103
48	Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. <i>Acta Oncologica</i> , 2006, 45, 627-629.	1.8	7
49	â€œBurned outâ€“phenomenon of the testis in retroperitoneal seminoma. <i>Acta Oncologica</i> , 2006, 45, 335-336.	1.8	15
50	Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. <i>Annals of Oncology</i> , 2006, 17, 1497-1503.	1.2	72
51	Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2083-2088.	7.0	6
52	Size of Breast Cancer Metastases in Axillary Lymph Nodes: Clinical Relevance of Minimal Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2005, 23, 1379-1389.	1.6	153
53	Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors. <i>Clinical Cancer Research</i> , 2004, 10, 6622-6628.	7.0	333
54	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. <i>Annals of Oncology</i> , 2004, 15, 1749-1759.	1.2	90

#	ARTICLE	IF	CITATIONS
55	Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. <i>Annals of Oncology</i> , 2004, 15, 1633-1639.	1.2	65
56	Adjuvant Therapy for Very Young Women with Breast Cancer: Response According to Biologic and Endocrine Features. <i>Clinical Breast Cancer</i> , 2004, 5, 125-130.	2.4	15
57	A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 779-790.	6.3	190
58	Chemoprevention of Breast Cancer with Fenretinide. <i>Drugs</i> , 2001, 61, 909-918.	10.9	27
59	Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. <i>Breast Cancer Research and Treatment</i> , 2001, 69, 21-27.	2.5	34
60	Chemoprevention of breast cancer: The Italian experience. , 2000, 77, 84-96.		22
61	Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. <i>Journal of Cellular Biochemistry</i> , 2000, 76, 311-321.	2.6	10
62	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. <i>International Journal of Cancer</i> , 2000, 87, 601-605.	5.1	20
63	Hormonal Therapy and Chemoprevention. <i>Breast Journal</i> , 2000, 6, 317-323.	1.0	6
64	Fenretinide and cancer prevention. <i>Current Oncology Reports</i> , 2000, 2, 263-270.	4.0	25
65	Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999, 53, 145-151.	2.5	12
66	Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. , 1998, 76, 787-790.		41
67	Socioeconomic status and survival of gastric cancer patients. <i>European Journal of Cancer</i> , 1998, 34, 537-542.	2.8	35
68	Correlation between plasma transforming growth factor- β 1 and second primary breast cancer in a chemoprevention trial. <i>European Journal of Cancer</i> , 1998, 34, 999-1003.	2.8	20
69	Long-term effects of fenretinide on retinal function. <i>European Journal of Cancer</i> , 1997, 33, 80-84.	2.8	29
70	Presence and Distribution of Growth Factors in Breast Cyst Fluid. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 542-549.	3.8	9
71	Epidermal growth factor content of breast cyst fluids from women with breast cancer or proliferative disease of the breast. <i>Breast Cancer Research and Treatment</i> , 1995, 33, 219-224.	2.5	8
72	The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1. <i>European Journal of Cancer</i> , 1995, 31, 420-421.	2.8	3

#	ARTICLE	IF	CITATIONS
73	Effect of the Synthetic Retinoid Fenretinide on Dark Adaptation and the Ocular Surface. Journal of the National Cancer Institute, 1994, 86, 105-110.	6.3	59
74	Phase IIa Study of Fenretinide in Superficial Bladder Cancer, Using DNA Flow Cytometry as an Intermediate End Point. Journal of the National Cancer Institute, 1994, 86, 138-140.	6.3	58
75	Presence of immunoassayable transforming growth factor- β 21 (tgf- β 21) in breast cyst fluid (BCF): Relationship with the intracystic electrolyte and epidermal-growth-factor (EGF) content. International Journal of Cancer, 1994, 59, 725-727.	5.1	4
76	Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer. European Journal of Cancer, 1994, 30, 1909-1910.	2.8	10
77	Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?. British Journal of Cancer, 1994, 69, 617-619.	6.4	7
78	Breast cancer chemoprevention: Studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. Journal of Cellular Biochemistry, 1993, 53, 226-233.	2.6	20
79	Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. European Journal of Endocrinology, 1993, 129, 315-321.	3.7	11
80	Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint. Journal of Cellular Biochemistry, 1992, 50, 139-147.	2.6	22
81	EGF in breast cyst fluid: Relationships with intracystic androgens, estradiol and progesterone. International Journal of Cancer, 1991, 47, 523-526.	5.1	21